Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery: A Non- Interventional, Observational Study
| Registry | NCT07581548, acronym DRY-CAT |
|---|---|
| Status | Not yet recruiting |
| Study type | Observational |
| Enrollment | 300 (Estimated) |
| Sponsor | Democritus University of Thrace (Other) |
| Conditions | Cataract, Dry Eye |
| Interventions | Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max), Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo), Sodium Hyaluronate 0.2% and Amino acids drops (Helenvision ultra) (Drug) |
| Dates | start 2026-05-01 (estimated), primary completion 2026-12-31 (estimated), completion 2027-05-01 (estimated), first posted 2026-05-12, last updated 2026-05-12 |
| Locations | 1 site in Greece |
Related Papers Related Patents Related Grants Related Experts
All trials for Cataract All trials for Dry Eye All trials of Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max) All trials of Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo)
The primary objective of this study is the assessment of three tear substitute formulations in terms of postoperative discomfort following cataract extraction surgery by means of phacoemulsification and intraocular lens implantation.
Participants will be recruited from the Cataract Service of the University Hospital of Alexandroupolis (UHA). All participants will be randomly assigned to three study groups. Study group 1 will receive a fixed combination of chloramphenicol and dexamethasone (Dexachlor, Cooper, Greece) quid for 4 weeks and 0.15 % sodium hyaluronate \& Dexpanthenol 2% (Hylopan max, Zwitter, Greece) quid for 12 weeks. Study group 2 will receive a fixed combination of chloramphenicol and dexamethasone (Dexachlor, Cooper, Greece) quid for 4 weeks and 0.15 % sodium hyaluronate \& Trehalose 3% (Thealoz duo, Thea, Greece) quid for 12 weeks. Study group 3 will receive a fixed combination of chloramphenicol and dexamethasone (Dexachlor, Cooper, Greece) quid for 4 weeks and 0.2% sodium hyaluronate and amino acids (Helenvision Ultra, Pharmex, Greece) quid for 12 weeks.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Study Group 1 | Drug: Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max) | Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops (Hylopan max) | |
| Study Group 2 | Drug: Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo) | Sodium Hyaluronate 0.15% and Trehalose 3% drops (Thealoz duo) | |
| Study Group 3 | Drug: Sodium Hyaluronate 0.2% and Amino acids drops (Helenvision ultra) | Sodium Hyaluronate 0.2% and Amino acids drops (Helenvision ultra) |
Sex: All, ages: 45 Years to 85 Years
Inclusion Criteria: Diagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale Exclusion Criteria: 1. Former incisional surgery 2. Former diagnosis of corneal disease 3. Autoimmune diseases 4. Mental diseases
| Facility | City | Country | Status |
|---|---|---|---|
| University Hospital of Alexandroupolis | Alexandroupoli, Evros | Greece |